Sorafenib Tosylate(Bay 43-9006 Nexavar)

位置：首页 > 产品库 > Sorafenib Tosylate(Bay 43-9006 Nexavar)

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	475207-59-1
规格:	≥98%

包装与价格：

包装	价格(元)
250mg	询价
500mg	询价
1g	询价
2g	询价
5g	询价
10g	询价
25g	询价
50g	询价

理化性质和储存条件

Molecular Weight (MW)	637.03
Formula	C21H16ClF3N4O3.C7H8O3S
CAS No.	475207-59-1(tosylate);
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 127 mg/mL (199.4 mM)
	Water: <1 mg/mL (slightly soluble or insoluble)
	Ethanol: <1 mg/mL
Synonym	BAY 43-9006 tosylate; BAY549085; BAY-439-006; BAY 549085; BAY-439006 tosylate; BAY 439006; BAY439006 tosylate; BAY-549085; Nexavar; SFN.

实验参考方法

General	Oral administration of Sorafenib tosylate (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity.
Animal model	Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
Formulation	Cremophor EL/ethanol (1:1) as 4-fold (4 × stock solution), and diluted to 1 × with w
Dosages	60 mg/kg
Administration	Administered orally once a day
Reference	[1] Wilhelm SM, et al. Cancer Res, 2004, 64(19), 7099-7109.

生物活性

The number of nuclei breaking the internal limiting membrane (ILM). A: Controlled group; B: ROP group; C: Vehicle-treated ROP group; D: Low doses sorafenib-treated ROP group; E: Middle doses sorafenib-treated ROP group; F: High dose sorafenib-treated ROP group.